{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate&page=57",
    "query": {
      "condition": "Prostate",
      "page": 57
    },
    "page_size": 10
  },
  "pagination": {
    "page": 57,
    "page_size": 10,
    "total_count": 4170,
    "total_pages": 417,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate&page=58&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate&page=56&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T01:38:53.728Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00111618",
      "title": "Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "AS1404 (DMXAA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Antisoma Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 70,
      "start_date": "2005-05",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2009-01-30",
      "last_synced_at": "2026-10-29T01:38:53.728Z",
      "location_count": 27,
      "location_summary": "Alhambra, California • Bakersfield, California • Burbank, California + 23 more",
      "locations": [
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00111618"
    },
    {
      "nct_id": "NCT02849990",
      "title": "A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Prostate Adenocarcinoma AJCC v7",
        "Stage III Prostate Cancer AJCC v7",
        "Stage IV Prostate Adenocarcinoma AJCC v7",
        "Stage IV Prostate Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Degarelix",
          "type": "DRUG"
        },
        {
          "name": "Indomethacin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2017-03-09",
      "completion_date": "2020-12-10",
      "has_results": true,
      "last_update_posted_date": "2022-01-13",
      "last_synced_at": "2026-10-29T01:38:53.728Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02849990"
    },
    {
      "nct_id": "NCT01816048",
      "title": "NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostatic Neoplasms",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "TAK-700",
          "type": "DRUG"
        },
        {
          "name": "Fluorine F 18 Sodium Fluoride",
          "type": "RADIATION"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2013-05",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2019-12-09",
      "last_synced_at": "2026-10-29T01:38:53.728Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01816048"
    },
    {
      "nct_id": "NCT02034825",
      "title": "Multi-site Decision Impact Study for Decipher",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Decipher Questionnaire",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "GenomeDx Biosciences Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 50,
      "start_date": "2013-01",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2016-02-29",
      "last_synced_at": "2026-10-29T01:38:53.728Z",
      "location_count": 3,
      "location_summary": "Menlo Park, California • Celebration, Florida • New York, New York",
      "locations": [
        {
          "city": "Menlo Park",
          "state": "California"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02034825"
    },
    {
      "nct_id": "NCT04754191",
      "title": "Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enfortumab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 34,
      "start_date": "2022-06-05",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-29T01:38:53.728Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04754191"
    },
    {
      "nct_id": "NCT02380274",
      "title": "Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer",
        "Castration-resistant Prostate Cancer",
        "Metastatic Prostate Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1030,
      "start_date": "2015-03-27",
      "completion_date": "2021-01-14",
      "has_results": false,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-10-29T01:38:53.728Z",
      "location_count": 148,
      "location_summary": "Homewood, Alabama • Anchorage, Alaska • Phoenix, Arizona + 132 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02380274"
    },
    {
      "nct_id": "NCT02001623",
      "title": "Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovary Cancer",
        "Cervix Cancer",
        "Endometrium Cancer",
        "Bladder Cancer",
        "Prostate Cancer (CRPC)",
        "Esophagus Cancer",
        "Lung Cancer(NSCLC)",
        "Squamous Cell Carcinoma of the Head and Neck (SCCHN)"
      ],
      "interventions": [
        {
          "name": "Tisotumab Vedotin (HuMax-TF-ADC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 195,
      "start_date": "2013-11-30",
      "completion_date": "2019-05-02",
      "has_results": true,
      "last_update_posted_date": "2021-12-29",
      "last_synced_at": "2026-10-29T01:38:53.728Z",
      "location_count": 8,
      "location_summary": "Orange, California • New Haven, Connecticut • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02001623"
    },
    {
      "nct_id": "NCT05915442",
      "title": "Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oligometastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Quemliclustat",
          "type": "DRUG"
        },
        {
          "name": "Etrumadenant",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Catherine Spina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "18 Years to 99 Years · Male only"
      },
      "enrollment_count": 23,
      "start_date": "2023-07-01",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2025-05-20",
      "last_synced_at": "2026-10-29T01:38:53.728Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05915442"
    },
    {
      "nct_id": "NCT01996852",
      "title": "Improving Erectile Function and Quality of Life After Prostate Cancer Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer",
        "Erectile Dysfunction Following Radical Prostatectomy",
        "Erectile Dysfunction Following Simple Prostatectomy",
        "Erectile Dysfunction"
      ],
      "interventions": [
        {
          "name": "Cognitive-behavioral Meetings",
          "type": "BEHAVIORAL"
        },
        {
          "name": "sildenafil citrate",
          "type": "DRUG"
        },
        {
          "name": "Vacuum Constriction Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "21 Years and older · Male only"
      },
      "enrollment_count": 34,
      "start_date": "2013-07",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2019-05-10",
      "last_synced_at": "2026-10-29T01:38:53.728Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01996852"
    },
    {
      "nct_id": "NCT02522715",
      "title": "Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Stage IV Prostate Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 37,
      "start_date": "2015-08-13",
      "completion_date": "2027-01-01",
      "has_results": true,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-29T01:38:53.728Z",
      "location_count": 3,
      "location_summary": "Portland, Oregon • Seattle, Washington",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02522715"
    }
  ]
}